Tirzepatide

Description

Tirzepatide Peptide for Sale — Research-Grade GIP/GLP-1 Dual Agonist

Tirzepatide peptide for sale for laboratory research — tirzepatide (LY3298176) is a 39-amino-acid dual GIP/GLP-1 receptor agonist built on the native GIP sequence, with a C20 fatty diacid moiety enabling albumin binding and a half-life of approximately five days.

What Is Tirzepatide?

Tirzepatide is the first “twincretin” — a single molecule engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Mechanism: GLP-1 receptor activity drives glucose-dependent insulin secretion, slowed gastric emptying and appetite suppression, while the GIP arm is associated in research with improved insulin sensitivity and adipose tissue signalling. The fatty diacid modification binds albumin, extending the half-life to roughly 117 hours in clinical research protocols.

Tirzepatide Research Findings

In the SURMOUNT-1 phase 3 trial, tirzepatide produced a mean body weight reduction of 20.9% at 72 weeks at the 15 mg dose in adults with obesity — the largest reduction reported for a dual agonist. In the SURPASS diabetes program, HbA1c reductions exceeded 2% in multiple arms, and SURPASS-2 reported superiority over semaglutide 1 mg on both glycaemic and weight endpoints. Ongoing research examines adipose remodelling, hepatic fat reduction and insulin-sensitivity mechanisms attributable to the GIP component.

Tirzepatide vs Retatrutide

Tirzepatide is a dual agonist (GIP + GLP-1), while retatrutide (triple agonist) adds glucagon receptor activity as a third mechanism, driving elevated resting energy expenditure on top of the incretin effects. In comparative research, tirzepatide serves as the benchmark dual-incretin compound against which triple agonists and single agonists such as semaglutide are measured.

Tirzepatide Research Peptide — Purity & Testing

VMAX tirzepatide is supplied as a lyophilized research peptide verified to ≥99% purity by HPLC and mass spectrometry, with a lot-matched Certificate of Analysis available for each batch.

Storage & Reconstitution

Handling: Lyophilized peptide. Store sealed at -20°C for long-term stability or 2-8°C short-term. Reconstitute with bacteriostatic water. After reconstitution, store at 2–8°C and avoid repeated freeze-thaw cycles.
For research purposes only. Not for human consumption. This material is intended exclusively for in-vitro laboratory and preclinical research applications conducted by qualified personnel.

Is VMAX tirzepatide third-party tested?

Yes our tirzepatide is third party tested in the USA

✓
Lab Verified > 99% purity · View lab results →

What is the purity of this tirzepatide?

Tirzepatide is supplied as a lyophilized research compound verified to ≥99% purity by HPLC and mass spectrometry.

How should tirzepatide be stored?

Store the lyophilized peptide sealed at -20°C for long-term stability, or 2–8°C short-term. After reconstitution, store at 2–8°C and avoid repeated freeze-thaw cycles.

What is the difference between tirzepatide and retatrutide?

Tirzepatide is a dual agonist activating the GIP and GLP-1 receptors, while retatrutide is a triple agonist that adds glucagon receptor activity, associated in research with increased energy expenditure alongside the incretin effects.

Is this tirzepatide for human use?

No. This material is sold strictly for in-vitro laboratory and preclinical research by qualified personnel. It is not for human or veterinary use.

What vial sizes are available?

Tirzepatide is available in multiple vial sizes — select your preferred option on this product page.